16. November 2009 06:21
BioMarin Pharmaceutical Inc. announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility. To ensure that patients are not exposed to foreign particles during product administration, Genzyme has issued a "Dear Doctor" letter to all physicians treating patients with enzyme replacement products that it markets, including Aldurazyme.
[More]
6. November 2009 02:24
BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024.
[More]
27. October 2009 06:28
Reportlinker Adds Direct-To-Consumer Genetic Testing: Business Prospects in the United States
[More]
c317af26-2bd6-4e85-8cb2-9579ecc56e8b|0|.0
Posted in: Device / Technology News
Tags: Biomarker, Cancer, CDC, Cell, Cystic Fibrosis, DNA, Fibrosis, Genetics, Genomics, Huntington's Disease, Medicaid, Medicare, Ovarian Cancer, Phenylketonuria, Tay-Sachs Disease
27. October 2009 00:45
BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
[More]
489d6b68-cad2-4b14-85b5-5d507c0de645|0|.0
Posted in: Business / Finance
Tags: Acute Lymphoblastic Leukemia, Antibiotic, Autoimmune Disease, Calcium, Cancer, Cell, Chemotherapy, Constipation, Education, Impotence, Leukemia, Lung Cancer, Multiple Sclerosis, Oncology, Phenylketonuria, Prostate Cancer, Radiation Therapy, Small Cell Lung Cancer
1. October 2009 07:10
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent and Trademark Office has allowed claims covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food, based on the discovery that food increases the bioavailability of Kuvan. The company expects that the patent, which expires in 2024, will officially issue later this year.
[More]
23. September 2009 00:22
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has initiated treatment in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Initial top-line results are expected in mid-2010.
[More]
26. August 2009 23:54
Genetic researchers at Children's Memorial Hospital, Chicago, are aggressively identifying adult patients who suffer from the genetic disorder, Phenylketonuria (PKU), and are presenting those findings at the 11th International Congress of Inborn Errors of Metabolism in San Diego, August 29 through September 2.
[More]
30. March 2009 23:26
For people with the genetic condition known as phenylketonuria (PKU), diet is a constant struggle.
[More]
30. March 2009 22:36
BioMarin Pharmaceutical Inc. has announced that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan (sapropterin dihydrochloride) in the treatment of phenylketonuria (PKU).
[More]
15. January 2009 04:51
PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).
[More]
10. December 2008 12:41
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.
[More]
8802016c-0f8d-41a0-8515-55271ea27a1e|0|.0
Posted in: Pharmaceutical News
Tags: Abdominal Pain, Amino Acid, Brain, Cough, Diarrhea, Diet, Metabolism, Nervous System, Phenylketonuria, Rare Disease, Serotonin, Sore Throat, Tryptophan, Vomiting
13. May 2008 19:58
A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns Hopkins shows.
[More]
5fea070c-333d-48db-a417-608645c36e63|0|.0
Posted in: Drug Trial News
Tags: Antioxidant, Blood Pressure, Brain, Cancer, Cardiology, Cardiovascular Disease, Fibrosis, Folic Acid, Heart Failure, Hypertension (High Blood Pressure), Magnetic Resonance Imaging (MRI), Metabolism, Nitric Oxide, Phenylketonuria, Stress, Stress Related, Transplant, Viagra (Sildenafil citrate), Vitamin C, Vitamin E, Vitamin K
12. May 2008 20:51
The demand for alternative sweeteners to sugar is increasing at a rate of 8% per year. The market is showing more and more interest in natural sweeteners compared to synthetic ones. This has been reflected in a study carried out by researchers at the Universidad Miguel Hernández (UMH) in Elche, Alicante.
[More]
29. April 2008 17:31
Enzolve Technologies, a UCD spin-out company based at NovaUCD the Innovation and Technology Transfer Centre at University College Dublin, has received substantial investment from Enterprise Ireland under the National Development Plan (2007-2013) and private investors.
[More]
10. January 2008 06:37
No pizza. No ice cream. No hotdogs and definitely no hamburgers. What sounds like a list of banned food for someone trying to lose weight is actually a way of life for children with a rare metabolic disorder, phenylketonuria (PKU), which prevents digestion of an essential amino acid found in most meats, eggs, dairy products, nuts and breads.
[More] 
Subscribe